DRS

Georgia Urology promotes four practice physicians to team of shareholders

Retrieved on: 
Wednesday, November 16, 2022
Erectile dysfunction, Health, Roswell, Male, Laparoscopy, Kidney, Overactive bladder, Infertility, Washington University School of Medicine, Woman, Kidney stone disease, Kidney cancer, Hematuria, Medical college, Physician, Peyronie's disease, Pediatrics, Urology, Man, Breast implant, Men's Health, Medical College of Georgia, DRS, Pleasure, Multimedia, Interstitial cystitis, Patient, Hillandale, Prostate cancer, Prostate, Incontinence, Disease, George Washington University School of Medicine & Health Sciences, Healthcare, Dentistry, Medical imaging

ATLANTA, Nov. 16, 2022 /PRNewswire/ -- Georgia Urology –the largest urology practice in Georgia– appoints four practice physicians to its team of shareholders. Drs. Daniel Belew, Michael Kemper, Joseph Song, and Bryce Wyatt are receiving the honor due to their clinical excellence and outstanding patient care.

Key Points: 
  • Daniel Belew, Michael Kemper,
    ATLANTA, Nov. 16, 2022 /PRNewswire/ -- Georgia Urology the largest urology practice in Georgia appoints four practice physicians to its team of shareholders.
  • With these doctors becoming shareholders, patients can be confident about their doctors' long-term commitment to Georgia Urology and the communities they serve.
  • "It is an honor for me to welcome and congratulate Georgia Urology's newest shareholders," says Dr. Hal Scherz, Georgia Urology President.
  • Georgia Urology is the largest urology practice in Georgia with more than 30 locations and seven ambulatory surgery centers across metro Atlanta.

New Research from NWEA Highlights a Widening Academic Divide

Retrieved on: 
Wednesday, November 16, 2022
Growth, Gaps, Reading, Knowledge, Learning, Student, Association, Schiller Park School District 81, School, DRS, Research, Multimedia, NWEA, Policy, Achievement, Research report, Superintendent, Solution, Tutoring

PORTLAND, Ore., Nov. 16, 2022 /PRNewswire/ -- NWEA –  a not-for-profit, research and educational services organization serving K-12 students – announced today new research findings that examined to what degree students' reading and math test scores have become more variable during the pandemic, and how achievement gains across the pandemic compare to pre-pandemic trends for students who were low- or high-achieving before the pandemic started.

Key Points: 
  • Academic diversity in student achievement is not a new concept to educators who each fall prepare instructional plans that must meet a range of academic skills and knowledge of their incoming students.
  • For example, a typical fifth-grade pre-pandemic classroom included students who, on average, ranged up to seven grade levels (above and below).
  • "The continued impact of the pandemic requires focus, new strategies, creative solutions, and collaboration between educators and families," said Dr. Chase Nordengren,principal research lead for Effective Instructional Strategies at NWEA.
  • Learning gaps across grade levels have created conditions in schools that demand educators meet students at their individual instructional level to target their personal academic needs.

BRAINBox Solutions Enrolls 1000th Patient in Pivotal, HeadSMART II Clinical Study of BRAINBox TBI Concussion Diagnostic and Prognostic Test

Retrieved on: 
Monday, November 14, 2022
Algorithm, Adult, Doctor of Philosophy, Virginia Tech Carilion School of Medicine and Research Institute, UCSF, Prognosis, Traumatic brain injury, Spine, MD, Solution, Gold standard, Brainbox, User experience, Scoliosis, Research, University, Baylor University, Brain, National Institutes of Health, Baylor College of Medicine, DRS, Department, Neuroimaging, Standard of care, Post-concussion syndrome, Frontiers, Patient, Special, Risk, ATE, Clinical trial, Urgent care center, Emergency medicine, MRI, Review, National, Diagnosis, Trauma center, TBI, SAB, Concussion, CT, SFGH, Pharmaceutical industry, Medical device, Medical imaging, Neurology

RICHMOND, Va., Nov. 14, 2022 /PRNewswire/ -- BRAINBox Solutions today announced that the company has enrolled the 1,000th patient in the pivotal, HeadSMART II study of its concussion diagnostic and prognostic test, BRAINBox TBI.

Key Points: 
  • RICHMOND, Va., Nov. 14, 2022 /PRNewswire/ -- BRAINBox Solutions today announced that the company has enrolled the 1,000th patient in the pivotal, HeadSMART II study of its concussion diagnostic and prognostic test, BRAINBox TBI.
  • "We are developing the BRAINBox TBI (Traumatic Brain Injury) test as the first objective test to aid in the diagnosis of concussion and to provide an assessment of the risk of post-concussive symptoms," said Donna Edmonds, BRAINBox Solutions' CEO.
  • As such, the trial has been rigorously designed in collaboration with leading experts in traumatic brain injury and emergency medicine.
  • Additionally, the company isengaged a Pilot Study for a Pediatric Test for individuals under the age of 18, aimed at the same claims as the adult study.

Tudor Gold Corp. and Goldstorm Metals Corp. Announce Closing of Spin-out Arrangement and Listing of Goldstorm Metals Corp.

Retrieved on: 
Friday, November 11, 2022
SEDAR, TUC, Kings, Company, The, KSM, Golden Triangle, Brucejack/Bowser Aerodrome, Seabridge Gold, Technical report, Letter, Computershare, TSX Venture Exchange, Mediumwave transmitter Flevoland, Crown Property Bureau, FSE, Arrangement, Canada Business Corporations Act, DRS, News, Equilateral triangle, Security (finance)

As a result of the Arrangement, Goldstorm ceased to be a wholly-owned subsidiary of Tudor Gold, and shareholders of Tudor Gold became shareholders of Goldstorm.

Key Points: 
  • As a result of the Arrangement, Goldstorm ceased to be a wholly-owned subsidiary of Tudor Gold, and shareholders of Tudor Gold became shareholders of Goldstorm.
  • Additionally, the Goldstorm Shares were listed on the TSX Venture Exchange (the "TSXV") under ticker symbol "GSTM" as at the close of business on November 10, 2022.
  • Tudor Gold retains its remaining assets and working capital and will continue as a precious and base metals exploration and development company.
  • Tudor Gold shareholders who hold their Old Tudor Shares through an intermediary are encouraged to contact their intermediaries if they have any questions.

Tudor Gold Corp. and Goldstorm Metals Corp. Announce Closing of Spin-Out Arrangement and Listing of Goldstorm Metals Corp.

Retrieved on: 
Friday, November 11, 2022
SEDAR, TUC, Kings, Company, The, KSM, Golden Triangle, Brucejack/Bowser Aerodrome, Seabridge Gold, Technical report, Letter, Computershare, TSX Venture Exchange, Mediumwave transmitter Flevoland, Crown Property Bureau, FSE, Arrangement, Canada Business Corporations Act, DRS, News, Equilateral triangle, Security (finance)

As a result of the Arrangement, Goldstorm ceased to be a wholly-owned subsidiary of Tudor Gold, and shareholders of Tudor Gold became shareholders of Goldstorm.

Key Points: 
  • As a result of the Arrangement, Goldstorm ceased to be a wholly-owned subsidiary of Tudor Gold, and shareholders of Tudor Gold became shareholders of Goldstorm.
  • Additionally, the Goldstorm Shares were listed on the TSX Venture Exchange (the "TSXV") under ticker symbol "GSTM" as at the close of business on November 10, 2022.
  • Tudor Gold retains its remaining assets and working capital and will continue as a precious and base metals exploration and development company.
  • Tudor Gold shareholders who hold their Old Tudor Shares through an intermediary are encouraged to contact their intermediaries if they have any questions.

Asetek SimSports® Unveils Direct Drive Wheelbases And Formula Wheel Bringing Full Immersion To Sim Racing

Retrieved on: 
Friday, November 11, 2022
Formula, Skewer, F1, Software, Sale, Carbon, Electronics, Sim, Immersion, Glass, Forte, Color, VAT, Solution, ARGB, OEM, DRS, Invicta, Time, Hardness, Mobile phone, Video game console, Online shopping, Asetek

AALBORG, Denmark, Nov. 11, 2022 /PRNewswire/ -- Asetek, the no-compromise sim racing company and innovator of gaming hardware for next-level immersive gaming experiences, today announced its offering of high-performance Invicta™ and Forte® wheelbases and a Forte® Formula wheel, bringing full immersion to sim racing. Designed and developed in collaboration with F1 racer Kevin Magnussen, Asetek has optimized its electronics, firmware, and software, to maximize fidelity, customization and ease-of-use. With Asetek SimSports® wheelbases and the Formula steering wheel, sim racers of all levels can experience the feel of a real racecar while being able to customize settings regardless of the car, track, and conditions. 

Key Points: 
  • AALBORG, Denmark, Nov. 11, 2022 /PRNewswire/ -- Asetek, the no-compromise sim racing company and innovator of gaming hardware for next-level immersive gaming experiences, today announced its offering of high-performance Invicta and Forte wheelbases and a Forte Formula wheel, bringing full immersion to sim racing.
  • Asetek SimSports Invicta Wheelbase features an unrivaled 27Nm direct drive motor, state-of-the-art Quick Release, and a plethora of mounting options.
  • The Forte Wheelbase incorporates an 18Nm direct drive motor and includes the same Asetek SimSports Quick Release and mounting options as its big brother, the Invicta Wheelbase.
  • Designed as plug'n'play, the wheelbases and Forte Formula Wheel work out of the box by installing Asetek SimSports RaceHub software, which provides sim racers of all levels an abundance of advanced features and customization options.

Asetek SimSports® Unveils La Prima™ Pedals, Wheelbase and Formula Wheel Bundle For Immersive Sim Racing

Retrieved on: 
Friday, November 11, 2022
Formula, Skewer, Sale, Carbon, Sibling, Glass, Forte, Shoe, Color, VAT, Solution, OEM, ARGB, La Prima Espresso Company, DRS, Light-emitting diode, La, Invicta, Pedal, Brake, Time, Hardness, Video game console, Oil, Mobile phone, Hydraulic machinery, Mail order, Asetek

AALBORG, Denmark, Nov. 11, 2022 /PRNewswire/ -- Asetek, the no-compromise sim racing company and innovator of gaming hardware for next-level immersive gaming experiences, today unveiled its high-quality and easily upgradeable La Prima™ Bundle, providing sim racers an authentic racecar feel at a highly competitive price point. The bundle includes the La Prima™ Throttle and Brake Pedal Set, 12Nm wheelbase, and Formula Wheel, along with an optional La Prima™ Clutch. Now aspiring sim racers can get the ultimate racecar racing experience with the performance and reliability of Asetek SimSports® gear, along with unparalleled upgradability only offered by Asetek.

Key Points: 
  • The bundle includes the La Prima Throttle and Brake Pedal Set, 12Nm wheelbase, and Formula Wheel, along with an optional La Prima Clutch.
  • Similarly, sim racers can upgrade their La Prima Wheelbase and Formula Wheel to the more powerful 18Nm Forte Wheelbase and Forte Formula Wheel, which include even more features and functionality.
  • La Prima Throttle and Brake Pedal Set:
    With the same brake as the Forte pedals, the La Prima Pedal Set features Asetek's proprietary 2-stage M.L.C.P.C.
  • La Prima Formula Steering Wheel:
    The La Prima Formula wheel provides sim racers the strength and stiffness of a real racecar wheel, with the added benefit of allowing the user to easily upgrade or personalize over time.

9th Annual “N20” Neuroscience20 (Brain, Spine, and Mental Health) Summit to Shed Light On $16T+ Global Cost of Neuro-psychiatric Disorders

Retrieved on: 
Friday, November 11, 2022
WBMF, GLOBE, Brain mapping, Neurological disorder, Neuro, Rehabilitation, Airlangga University, Partnership, Epilepsy, Indiana University Health Proton Therapy Center, USC Norris Comprehensive Cancer Center, Cervical spine disorder, Radiosurgery, Spine, Therapy, AP, DRS, Brain, Machine learning, National Center for Spinal Disorders, Policy, Publication, Program, Society for Brain Mapping and Therapeutics, Pain management, Awareness, Journal, SBMT, ME, Opioid, Society, COVID-19, Neurodegeneration, Pharmaceutical industry, N20, Neurosurgery, Neurovascular bundle, G20

Neurological disorders significantly impact the worlds economy due to their often chronic and life-threatening nature, creating a global disease burden.

Key Points: 
  • Neurological disorders significantly impact the worlds economy due to their often chronic and life-threatening nature, creating a global disease burden.
  • The N20 - an initiative of the Society for Brain Mapping and Therapeutics (SBMT) - is at the forefront of this worldwide collaboration to comprehensively raise awareness about brain, spine, and mental disorders.
  • We studied the cost of neuro-psychiatric and spine disorders to the world economy, and it took us almost a year to compile the data.
  • We discovered a total cost of over $16T annually to the world economy and $1.5T to the US economy.

Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 10, 2022
LRRK2, Investor, Traffic barrier, Stimulator of interferon genes, Adult, Research, Sale, Therapy, Policy, Company, Conference, Food, DYRK1A, APA, Atopic dermatitis, TTK, Compliance, U.S. Securities and Exchange Commission, Time, Pharmacokinetics, Autoimmunity, Inflammation, Patient, Acquisition, COVID-19, Leadership, CLK, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clinical trial, Coronavirus Scientific Advisory Board (Turkey), Down syndrome, Next, AD, Track, TSA, EDT, NDA, SAB, FDA, GLOBE, Intellectual property, Feedback, File, Private Securities Litigation Reform Act, MAD, DRS, SAD, Safety, Part, Part Two, Tyrosine kinase inhibitor, Insurance, Pharmaceutical industry, Vaccine, Security (finance), Video game, Fresh

BOULDER, Colo., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Key Points: 
  • To better align with our new strategic vision and plans, we recently rebranded the Company to Fresh Tracks Therapeutics, commented Robert Brown, Chief Executive Officer of Fresh Tracks.
  • In the second quarter of 2022, Fresh Tracks entered into an asset purchase agreement (APA) with Botanix SB Inc. (Botanix).
  • Fresh Tracks management will host a conference call today at 4:30 p.m. EDT to discuss the financial results and recent corporate developments.
  • Fresh Tracks Therapeutics is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.

IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System

Retrieved on: 
Thursday, November 10, 2022
GLOBE, RNA transfection, Private Securities Litigation Reform Act, Organic acid, Immunoglobulin G, PCR, Vaccine, U.S. Securities and Exchange Commission, Severe acute respiratory syndrome coronavirus 2, HIV/AIDS, Immunotherapy, Research, Risk, Technology, COVID-19, Malaria, Pfizer–BioNTech COVID-19 vaccine, Therapy, DNA, DRS, Failure, NASDAQ, News, Gene expression, SARS, Bronchoalveolar lavage, Time, Infection, Crab-eating macaque, Cancer, Viral load, Neoplasm, Biotechnology, Tuberculosis, Patient, Security (finance), Animal, Interleukin, Rabies, Versatile, Antigen, Phase II, Pharmaceutical industry, LNP

LAWRENCEVILLE, N.J. and VANCOUVER, B.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, and Acuitas Therapeutics, a private biotechnology company focused on the development of delivery systems for nucleic acid vaccines and therapeutics based on lipid nanoparticles (LNP), today announced the signing of an agreement to evaluate the combination of IMUNON’s PLACCINE nucleic acid vaccine constructs formulated with Acuitas’ proprietary lipid delivery technology. Under the agreement, IMUNON will evaluate administration of its vector constructs formulated in various Acuitas LNP formulations for gene expression and immunogenicity in murine models.

Key Points: 
  • Under the agreement, IMUNON will evaluate administration of its vector constructs formulated in various Acuitas LNP formulations for gene expression and immunogenicity in murine models.
  • IMUNON has demonstrated initial proof-of-concept of its PLACCINE nucleic acid vaccine platform in rodent and non-human primate models through intramuscular (IM) administration of PLACCINE plasmid DNA constructs expressing single or multiple SARS-CoV-2 antigens in combination with the PLACCINE delivery system.
  • In October 2022, IMUNON reported partial results from an ongoing non-human primate study that examined a single plasmid DNA vector containing the SARS-CoV-2 Alpha variant spike antigen formulated with a synthetic DNA delivery system.
  • Analysis of blood samples for IgG and neutralizing antibodies showed evidence of immunogenicity in both PLACCINE- and mRNA-vaccinated subjects.